BioAge Labs, Inc.

NASDAQ:BIOA

Biotechnology

Healthcare
$4.77 +2.35%

+$0.47 today

Market cap
$179.59M
Beta
0.95
P/E (TTM)
-9.7
EPS (TTM)
-$2.12
52W Low $4.07High $24.00

Volume 0.64M

Average 0.46M

BIOA Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

BioAge Labs, Inc.NASDAQ: BIOA

Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares growth accelerates

Q1 FY2026 weighted avg shares of 42.48M shares rose 18.5% year over year, ahead of the +7.3% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 17.6% from the prior quarter. Over 3 fiscal years it compounded at +1.7% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +18.5% holds above the trailing-twelve-month pace of +7.3%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
42.48M+17.6% QoQ
Last fiscal yearDec 2025
35.93M+0.2% YoY
LTMMar 2026
37.57M+7.3% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+18.5%——
1 year+0.2%——
3-year CAGR+1.7%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
35.93M USD
Year-over-year change
+0.2%
3-year CAGR
+1.7%

Weighted Avg Shares vs competitors

How BIOA compares with its peers on the latest reported figures

  • BIOA's LTM Mar 2026 weighted avg shares of 37.57M shares is the 9th highest of the 10 companies compared; the peer median is 90.28M shares.
  • Its year-over-year change of +7.3% is the 7th highest of 9, against a peer median of +10.4%.
  • Over three fiscal years its annual growth of +1.7% compares with a peer median of +15.5%.
BIOA Competitors Peer median
Weighted Avg Shares for BIOA and competitors
Company Period LTM YoY 3-year CAGR
CGCCanopy Growth CorporationLTM Mar 2026298.22M +210.7%+300.6%
ALLOAllogene Therapeutics, Inc.LTM Mar 2026225.47M +9.3%+15.5%
HUMAHumacyte, Inc.LTM Mar 2026167.44M +37.1%+15.3%
CABACabaletta Bio, Inc.LTM Mar 202694.61M +91.6%+51.6%
EDITEditas Medicine, Inc.LTM Mar 202690.28M +9.3%+8.9%
AVIRAtea Pharmaceuticals, Inc.LTM Mar 202680.03M -5.4%-0.7%
ACBAurora Cannabis Inc.LTM Mar 202655.98M +3.6%+20.7%
TKNOAlpha Teknova, Inc.LTM Mar 202653.53M +11.4%+24.0%
BIOABioAge Labs, Inc.LTM Mar 202637.57M +7.3%+1.7%
LFCRLifecore Biomedical, Inc.LTM Mar 202637.34M —+5.7%
Peer median (excluding BIOA) 90.28M+10.4%+15.5%

Competitors are the stored peer set for BIOA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue0009M
Cost of Revenue0000
Gross Profit0009M
Gross Margin———100.0%
Research & Development30.52M33.89M59.04M73.97M
Selling, General & Admin9.45M14.51M19.16M27.81M
Operating Expenses39.97M48.4M78.19M101.78M
Depreciation & Amortization129K162K167K213K
EBITDA(39.35M)(55.9M)(68.58M)(79.7M)
EBITDA Margin———-886.0%
Operating Income(39.97M)(48.4M)(78.19M)(92.78M)
Operating Margin———-1031.5%
Interest Income465K2.43M9.63M13.09M
Interest Expense241K7.79M2.37M697K
Other Income / Expenses247K(15.45M)7.09M12.18M
Income Before Tax(39.72M)(63.85M)(71.11M)(80.61M)
Pre-Tax Margin———-896.1%
Income Tax Expense0000
Net Income(39.72M)(63.85M)(71.11M)(80.61M)
Net Margin———-896.1%
EPS (Basic)(1.16)(1.87)(1.98)(2.24)
EPS (Diluted)(1.16)(1.87)(1.98)(2.24)
Weighted Avg Shares34.17M34.2M35.85M35.93M
Weighted Avg Shares (Diluted)34.17M34.2M35.85M35.93M

BioAge Labs, Inc.

NASDAQ:BIOA

Intrinsic Alpha fair value

Locked

Current Price

$4.77

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.